Analiz Rodriguez
Concepts (281)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Neoplasms | 14 | 2023 | 287 | 4.870 |
Why?
| Glioblastoma | 9 | 2023 | 92 | 3.060 |
Why?
| Neurosurgery | 7 | 2023 | 32 | 1.760 |
Why?
| Central Nervous System Neoplasms | 2 | 2023 | 63 | 1.580 |
Why?
| Hematologic Neoplasms | 2 | 2023 | 99 | 1.570 |
Why?
| T-Lymphocytes | 6 | 2023 | 338 | 1.480 |
Why?
| Glioma | 3 | 2020 | 79 | 1.320 |
Why?
| Internship and Residency | 5 | 2023 | 443 | 1.120 |
Why?
| Biocompatible Materials | 5 | 2010 | 69 | 1.100 |
Why?
| Organoids | 3 | 2022 | 39 | 1.020 |
Why?
| Immunotherapy, Adoptive | 4 | 2023 | 156 | 0.950 |
Why?
| Lymphoma, B-Cell, Marginal Zone | 1 | 2023 | 23 | 0.890 |
Why?
| Humans | 48 | 2024 | 49974 | 0.840 |
Why?
| STAT2 Transcription Factor | 1 | 2021 | 7 | 0.800 |
Why?
| STAT1 Transcription Factor | 1 | 2021 | 26 | 0.800 |
Why?
| Li-Fraumeni Syndrome | 1 | 2021 | 13 | 0.800 |
Why?
| Biological Specimen Banks | 1 | 2021 | 21 | 0.780 |
Why?
| Physicians, Women | 3 | 2018 | 22 | 0.780 |
Why?
| Neurosurgical Procedures | 5 | 2023 | 121 | 0.770 |
Why?
| Foreign-Body Reaction | 3 | 2009 | 9 | 0.760 |
Why?
| Neoplasms | 4 | 2023 | 1235 | 0.750 |
Why?
| Melanoma | 2 | 2023 | 285 | 0.750 |
Why?
| Financing, Government | 1 | 2020 | 23 | 0.750 |
Why?
| Drug Discovery | 1 | 2021 | 85 | 0.740 |
Why?
| Hyperthermia, Induced | 2 | 2019 | 117 | 0.740 |
Why?
| Implants, Experimental | 3 | 2009 | 6 | 0.740 |
Why?
| National Institutes of Health (U.S.) | 1 | 2020 | 46 | 0.740 |
Why?
| DNA Modification Methylases | 1 | 2020 | 28 | 0.730 |
Why?
| Isocitrate Dehydrogenase | 1 | 2020 | 17 | 0.720 |
Why?
| DNA Repair Enzymes | 1 | 2020 | 44 | 0.720 |
Why?
| Sequence Analysis, RNA | 1 | 2020 | 91 | 0.690 |
Why?
| Societies, Medical | 1 | 2020 | 175 | 0.690 |
Why?
| Tumor Suppressor Proteins | 1 | 2020 | 128 | 0.680 |
Why?
| Phototherapy | 1 | 2019 | 45 | 0.680 |
Why?
| Paranasal Sinus Neoplasms | 1 | 2019 | 21 | 0.680 |
Why?
| Insurance, Health | 1 | 2020 | 126 | 0.670 |
Why?
| Cell Culture Techniques | 1 | 2019 | 99 | 0.670 |
Why?
| General Surgery | 1 | 2020 | 105 | 0.660 |
Why?
| Insurance Coverage | 1 | 2020 | 103 | 0.660 |
Why?
| Nanostructures | 1 | 2019 | 47 | 0.660 |
Why?
| Tumor Microenvironment | 5 | 2023 | 212 | 0.630 |
Why?
| Carcinoma | 1 | 2019 | 138 | 0.620 |
Why?
| Receptors, Antigen | 1 | 2017 | 2 | 0.600 |
Why?
| Biomedical Research | 1 | 2020 | 237 | 0.590 |
Why?
| Laser Therapy | 2 | 2016 | 84 | 0.560 |
Why?
| Recombinant Fusion Proteins | 1 | 2017 | 181 | 0.560 |
Why?
| Cell Line, Tumor | 6 | 2024 | 1403 | 0.530 |
Why?
| Syringomyelia | 1 | 2015 | 11 | 0.510 |
Why?
| Sexism | 1 | 2015 | 10 | 0.500 |
Why?
| Neoplasm Recurrence, Local | 3 | 2023 | 614 | 0.500 |
Why?
| Skin Neoplasms | 1 | 2020 | 488 | 0.500 |
Why?
| Specialties, Surgical | 1 | 2015 | 32 | 0.490 |
Why?
| Child | 6 | 2023 | 6847 | 0.480 |
Why?
| Neuronavigation | 1 | 2014 | 11 | 0.470 |
Why?
| Leadership | 1 | 2015 | 101 | 0.470 |
Why?
| Faculty, Medical | 1 | 2015 | 89 | 0.470 |
Why?
| Bone Screws | 1 | 2014 | 31 | 0.460 |
Why?
| Surgery, Computer-Assisted | 1 | 2014 | 55 | 0.440 |
Why?
| Lumbar Vertebrae | 1 | 2014 | 98 | 0.430 |
Why?
| Tomography, X-Ray Computed | 2 | 2019 | 1159 | 0.430 |
Why?
| Female | 21 | 2023 | 26472 | 0.430 |
Why?
| Teaching | 1 | 2014 | 116 | 0.430 |
Why?
| Education, Medical, Graduate | 1 | 2015 | 205 | 0.430 |
Why?
| Patient Care Team | 1 | 2014 | 254 | 0.410 |
Why?
| Materials Testing | 3 | 2009 | 58 | 0.410 |
Why?
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 154 | 0.400 |
Why?
| Disease Progression | 3 | 2020 | 825 | 0.390 |
Why?
| Trigeminal Neuralgia | 2 | 2021 | 6 | 0.380 |
Why?
| Spheroids, Cellular | 2 | 2021 | 25 | 0.370 |
Why?
| United States | 8 | 2023 | 4860 | 0.370 |
Why?
| Giant Cells, Foreign-Body | 2 | 2009 | 2 | 0.360 |
Why?
| Male | 15 | 2023 | 25241 | 0.340 |
Why?
| Lymphocyte Activation | 1 | 2010 | 172 | 0.330 |
Why?
| Stroke | 1 | 2014 | 492 | 0.320 |
Why?
| Transcriptome | 2 | 2021 | 315 | 0.320 |
Why?
| Multiple Myeloma | 1 | 2023 | 2929 | 0.320 |
Why?
| Career Choice | 3 | 2023 | 111 | 0.310 |
Why?
| Cytokines | 3 | 2019 | 612 | 0.310 |
Why?
| T-Lymphocyte Subsets | 1 | 2008 | 39 | 0.310 |
Why?
| Antineoplastic Agents | 3 | 2023 | 1171 | 0.310 |
Why?
| Spinal Fusion | 2 | 2022 | 70 | 0.300 |
Why?
| Aphids | 1 | 2007 | 2 | 0.300 |
Why?
| Pheromones | 1 | 2007 | 2 | 0.300 |
Why?
| Lung Neoplasms | 2 | 2024 | 606 | 0.300 |
Why?
| Solanum tuberosum | 1 | 2007 | 11 | 0.290 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 828 | 0.290 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2008 | 116 | 0.290 |
Why?
| Retrospective Studies | 8 | 2022 | 6108 | 0.280 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2008 | 164 | 0.280 |
Why?
| Adult | 9 | 2022 | 13236 | 0.270 |
Why?
| Stereotaxic Techniques | 2 | 2016 | 37 | 0.260 |
Why?
| Macrophages | 3 | 2021 | 363 | 0.240 |
Why?
| Imaging, Three-Dimensional | 2 | 2016 | 151 | 0.240 |
Why?
| Young Adult | 4 | 2022 | 3958 | 0.240 |
Why?
| History, 20th Century | 2 | 2021 | 99 | 0.230 |
Why?
| Combined Modality Therapy | 2 | 2016 | 637 | 0.230 |
Why?
| Middle Aged | 7 | 2022 | 12069 | 0.230 |
Why?
| Disease Management | 2 | 2015 | 174 | 0.230 |
Why?
| Mass Behavior | 1 | 2023 | 1 | 0.220 |
Why?
| Oncolytic Viruses | 1 | 2023 | 10 | 0.220 |
Why?
| Oncolytic Virotherapy | 1 | 2023 | 16 | 0.220 |
Why?
| Lymphoma | 1 | 2024 | 66 | 0.220 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 105 | 0.210 |
Why?
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2022 | 4 | 0.210 |
Why?
| Platybasia | 1 | 2022 | 5 | 0.210 |
Why?
| Zebrafish | 1 | 2023 | 54 | 0.210 |
Why?
| Animals | 11 | 2024 | 13187 | 0.210 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2023 | 259 | 0.210 |
Why?
| Aged | 7 | 2023 | 9310 | 0.200 |
Why?
| Antigens, Neoplasm | 1 | 2023 | 151 | 0.200 |
Why?
| Janus Kinase 1 | 1 | 2021 | 17 | 0.200 |
Why?
| Janus Kinase 2 | 1 | 2021 | 26 | 0.200 |
Why?
| Induced Pluripotent Stem Cells | 1 | 2022 | 42 | 0.200 |
Why?
| Retinal Dehydrogenase | 1 | 2021 | 10 | 0.200 |
Why?
| Nitriles | 1 | 2021 | 54 | 0.200 |
Why?
| Tissue Culture Techniques | 1 | 2021 | 40 | 0.200 |
Why?
| Germ-Line Mutation | 1 | 2021 | 61 | 0.200 |
Why?
| Biopsy | 2 | 2021 | 584 | 0.200 |
Why?
| Microvascular Decompression Surgery | 1 | 2021 | 2 | 0.200 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2021 | 57 | 0.200 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2021 | 88 | 0.190 |
Why?
| Cerebral Veins | 1 | 2021 | 15 | 0.190 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2021 | 136 | 0.190 |
Why?
| Pyrazoles | 1 | 2021 | 113 | 0.190 |
Why?
| Cell Adhesion | 3 | 2010 | 158 | 0.190 |
Why?
| Congresses as Topic | 1 | 2020 | 44 | 0.190 |
Why?
| Neoplasm Invasiveness | 1 | 2021 | 267 | 0.180 |
Why?
| Inpatients | 1 | 2022 | 190 | 0.180 |
Why?
| Cavernous Sinus | 1 | 2020 | 15 | 0.180 |
Why?
| Alcohol Oxidoreductases | 1 | 2020 | 13 | 0.180 |
Why?
| Databases as Topic | 1 | 2020 | 37 | 0.180 |
Why?
| Pyrimidines | 1 | 2021 | 192 | 0.180 |
Why?
| Medically Uninsured | 1 | 2020 | 45 | 0.180 |
Why?
| Skull Base Neoplasms | 1 | 2020 | 21 | 0.180 |
Why?
| Methylation | 1 | 2020 | 122 | 0.180 |
Why?
| Decompression, Surgical | 2 | 2022 | 51 | 0.180 |
Why?
| Infrared Rays | 1 | 2019 | 25 | 0.170 |
Why?
| Propensity Score | 1 | 2020 | 123 | 0.170 |
Why?
| Meningioma | 1 | 2020 | 46 | 0.170 |
Why?
| Meningeal Carcinomatosis | 1 | 2019 | 6 | 0.170 |
Why?
| Proteomics | 1 | 2022 | 329 | 0.170 |
Why?
| Meningeal Neoplasms | 1 | 2020 | 51 | 0.170 |
Why?
| Silicone Elastomers | 2 | 2009 | 8 | 0.170 |
Why?
| Polyethylene Terephthalates | 2 | 2009 | 10 | 0.170 |
Why?
| Neuralgia | 1 | 2020 | 62 | 0.170 |
Why?
| Thiotepa | 1 | 2019 | 5 | 0.170 |
Why?
| Cognition | 2 | 2019 | 338 | 0.170 |
Why?
| Lasers | 1 | 2019 | 123 | 0.170 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2019 | 74 | 0.160 |
Why?
| Neoplasm Metastasis | 1 | 2019 | 231 | 0.160 |
Why?
| Socioeconomic Factors | 1 | 2021 | 581 | 0.160 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 169 | 0.150 |
Why?
| Magnetic Resonance Imaging | 2 | 2015 | 1537 | 0.150 |
Why?
| Pilot Projects | 1 | 2020 | 699 | 0.150 |
Why?
| Healthcare Disparities | 1 | 2021 | 257 | 0.150 |
Why?
| Adolescent | 2 | 2021 | 6356 | 0.150 |
Why?
| Head and Neck Neoplasms | 1 | 2020 | 268 | 0.150 |
Why?
| Cell Proliferation | 3 | 2023 | 1007 | 0.140 |
Why?
| Chemoradiotherapy, Adjuvant | 1 | 2016 | 17 | 0.140 |
Why?
| Health Services Accessibility | 1 | 2021 | 398 | 0.140 |
Why?
| Neoplasm Staging | 1 | 2019 | 740 | 0.140 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2019 | 485 | 0.140 |
Why?
| Transverse Sinuses | 1 | 2016 | 5 | 0.140 |
Why?
| Immunohistochemistry | 1 | 2019 | 973 | 0.140 |
Why?
| Central Nervous System Vascular Malformations | 1 | 2016 | 13 | 0.140 |
Why?
| Intracranial Hypertension | 1 | 2016 | 31 | 0.140 |
Why?
| Rats, Sprague-Dawley | 3 | 2009 | 1597 | 0.140 |
Why?
| Oxygen | 1 | 2019 | 326 | 0.130 |
Why?
| Urinary Bladder, Neurogenic | 1 | 2015 | 11 | 0.130 |
Why?
| Muscular Dystrophies | 1 | 2015 | 15 | 0.130 |
Why?
| Sensation Disorders | 1 | 2015 | 11 | 0.130 |
Why?
| Watchful Waiting | 1 | 2015 | 27 | 0.130 |
Why?
| Unnecessary Procedures | 1 | 2015 | 21 | 0.130 |
Why?
| Intestinal Diseases | 1 | 2015 | 25 | 0.130 |
Why?
| Asymptomatic Diseases | 1 | 2015 | 36 | 0.130 |
Why?
| Cranial Irradiation | 1 | 2015 | 21 | 0.130 |
Why?
| Drug Implants | 1 | 2015 | 35 | 0.120 |
Why?
| Scoliosis | 1 | 2015 | 59 | 0.120 |
Why?
| Immunotherapy | 1 | 2016 | 238 | 0.120 |
Why?
| Gait Disorders, Neurologic | 1 | 2015 | 36 | 0.120 |
Why?
| Radiography | 1 | 2015 | 489 | 0.120 |
Why?
| Emergency Medicine | 1 | 2014 | 52 | 0.110 |
Why?
| Mice | 4 | 2024 | 5739 | 0.110 |
Why?
| Rats | 3 | 2009 | 3305 | 0.110 |
Why?
| Neurology | 1 | 2014 | 41 | 0.110 |
Why?
| Radiosurgery | 1 | 2015 | 118 | 0.110 |
Why?
| Comorbidity | 1 | 2015 | 615 | 0.110 |
Why?
| Behavior, Animal | 2 | 2019 | 181 | 0.100 |
Why?
| Aged, 80 and over | 2 | 2023 | 3129 | 0.100 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2023 | 211 | 0.100 |
Why?
| Treatment Outcome | 2 | 2020 | 5141 | 0.100 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2010 | 11 | 0.090 |
Why?
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 9 | 0.090 |
Why?
| Follow-Up Studies | 1 | 2015 | 2182 | 0.090 |
Why?
| Lectins, C-Type | 1 | 2010 | 30 | 0.090 |
Why?
| Interleukin-2 | 1 | 2010 | 72 | 0.090 |
Why?
| Surface Properties | 1 | 2010 | 72 | 0.090 |
Why?
| Cell Count | 1 | 2010 | 147 | 0.090 |
Why?
| Interleukin-13 | 1 | 2009 | 15 | 0.090 |
Why?
| Interleukin-4 | 1 | 2009 | 43 | 0.090 |
Why?
| Polyurethanes | 1 | 2009 | 9 | 0.080 |
Why?
| Maze Learning | 2 | 2019 | 35 | 0.080 |
Why?
| Interferon-gamma | 1 | 2010 | 177 | 0.080 |
Why?
| Chemokines | 1 | 2009 | 77 | 0.080 |
Why?
| Mice, Nude | 1 | 2009 | 252 | 0.080 |
Why?
| Cell Membrane | 1 | 2010 | 248 | 0.080 |
Why?
| Mice, Inbred BALB C | 1 | 2009 | 304 | 0.080 |
Why?
| Antigens, CD | 1 | 2010 | 219 | 0.080 |
Why?
| Granulocytes | 1 | 2008 | 26 | 0.080 |
Why?
| Immunity, Cellular | 1 | 2008 | 69 | 0.080 |
Why?
| Infant, Newborn | 1 | 2015 | 2772 | 0.080 |
Why?
| Hexanols | 1 | 2007 | 1 | 0.080 |
Why?
| Time Factors | 2 | 2019 | 2903 | 0.080 |
Why?
| Terpenes | 1 | 2007 | 16 | 0.080 |
Why?
| Plant Diseases | 1 | 2007 | 8 | 0.080 |
Why?
| Polytetrafluoroethylene | 1 | 2007 | 32 | 0.070 |
Why?
| Surgical Mesh | 1 | 2007 | 17 | 0.070 |
Why?
| Aldehydes | 1 | 2007 | 83 | 0.070 |
Why?
| Apoptosis | 2 | 2023 | 1101 | 0.070 |
Why?
| Flow Cytometry | 1 | 2010 | 476 | 0.070 |
Why?
| Virus Diseases | 1 | 2007 | 39 | 0.070 |
Why?
| Infant | 1 | 2015 | 3567 | 0.070 |
Why?
| Child, Preschool | 1 | 2015 | 3871 | 0.070 |
Why?
| Cells, Cultured | 1 | 2010 | 1573 | 0.070 |
Why?
| Prosencephalon | 1 | 2023 | 12 | 0.060 |
Why?
| Chick Embryo | 1 | 2023 | 82 | 0.060 |
Why?
| Tamoxifen | 1 | 2023 | 60 | 0.060 |
Why?
| Mice, Inbred C57BL | 2 | 2019 | 1816 | 0.060 |
Why?
| Mesencephalon | 1 | 2023 | 35 | 0.060 |
Why?
| Cerebral Ventricles | 1 | 2023 | 28 | 0.060 |
Why?
| Monensin | 1 | 2022 | 12 | 0.050 |
Why?
| Intracranial Pressure | 1 | 2022 | 30 | 0.050 |
Why?
| Nose | 1 | 2022 | 31 | 0.050 |
Why?
| Steroids | 1 | 2022 | 57 | 0.050 |
Why?
| Minority Groups | 1 | 2023 | 132 | 0.050 |
Why?
| Anniversaries and Special Events | 1 | 2021 | 3 | 0.050 |
Why?
| Medicare | 1 | 2023 | 246 | 0.050 |
Why?
| Trigeminal Nerve | 1 | 2021 | 8 | 0.050 |
Why?
| Monitoring, Physiologic | 1 | 2022 | 120 | 0.050 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2023 | 225 | 0.050 |
Why?
| Tretinoin | 1 | 2021 | 53 | 0.050 |
Why?
| Communication | 1 | 2023 | 246 | 0.050 |
Why?
| Decompression | 1 | 2020 | 2 | 0.050 |
Why?
| Trauma Centers | 1 | 2022 | 193 | 0.050 |
Why?
| Tumor Cells, Cultured | 1 | 2021 | 465 | 0.050 |
Why?
| Cell Movement | 1 | 2021 | 247 | 0.050 |
Why?
| Glucocorticoids | 1 | 2022 | 219 | 0.050 |
Why?
| Dexamethasone | 1 | 2022 | 430 | 0.040 |
Why?
| Cell Line | 1 | 2022 | 1000 | 0.040 |
Why?
| Injections, Intraperitoneal | 1 | 2019 | 54 | 0.040 |
Why?
| Receptors, AMPA | 1 | 2019 | 17 | 0.040 |
Why?
| Dentate Gyrus | 1 | 2019 | 17 | 0.040 |
Why?
| Dendritic Spines | 1 | 2019 | 21 | 0.040 |
Why?
| Protein Subunits | 1 | 2019 | 77 | 0.040 |
Why?
| Movement | 1 | 2019 | 82 | 0.040 |
Why?
| Registries | 1 | 2021 | 522 | 0.040 |
Why?
| Synapses | 1 | 2019 | 87 | 0.040 |
Why?
| Receptors, N-Methyl-D-Aspartate | 1 | 2019 | 127 | 0.040 |
Why?
| Faculty | 1 | 2018 | 72 | 0.040 |
Why?
| Certification | 1 | 2018 | 49 | 0.040 |
Why?
| Cross-Sectional Studies | 1 | 2023 | 1557 | 0.040 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 989 | 0.040 |
Why?
| Tissue Engineering | 2 | 2007 | 64 | 0.040 |
Why?
| Cadaver | 1 | 2016 | 97 | 0.030 |
Why?
| Personnel Selection | 1 | 2015 | 24 | 0.030 |
Why?
| RNA, Messenger | 1 | 2019 | 1105 | 0.030 |
Why?
| Mutation | 1 | 2021 | 1294 | 0.030 |
Why?
| Databases, Factual | 1 | 2018 | 658 | 0.030 |
Why?
| Salvage Therapy | 1 | 2014 | 139 | 0.030 |
Why?
| Sex Factors | 1 | 2015 | 691 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2014 | 454 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2014 | 402 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2014 | 466 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2014 | 577 | 0.030 |
Why?
| Brain | 1 | 2019 | 1328 | 0.020 |
Why?
| Regenerative Medicine | 1 | 2007 | 9 | 0.020 |
Why?
| Cell Communication | 1 | 2007 | 69 | 0.020 |
Why?
| Herniorrhaphy | 1 | 2007 | 23 | 0.020 |
Why?
| Tissue Adhesions | 1 | 2007 | 31 | 0.020 |
Why?
| Fibrosis | 1 | 2007 | 179 | 0.020 |
Why?
| Cell Differentiation | 1 | 2007 | 651 | 0.020 |
Why?
|
|
Rodriguez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|